Compare KODK & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KODK | ORGO |
|---|---|---|
| Founded | 1880 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.6M | 624.4M |
| IPO Year | N/A | N/A |
| Metric | KODK | ORGO |
|---|---|---|
| Price | $8.86 | $4.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 2.0M | ★ 3.2M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,045,000,000.00 | $465,218,000.00 |
| Revenue This Year | N/A | $8.14 |
| Revenue Next Year | N/A | $6.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.24 |
| 52 Week Low | $4.93 | $2.61 |
| 52 Week High | $9.31 | $7.08 |
| Indicator | KODK | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 70.42 | 43.04 |
| Support Level | $7.50 | $4.92 |
| Resistance Level | $8.67 | $5.83 |
| Average True Range (ATR) | 0.43 | 0.35 |
| MACD | 0.11 | -0.13 |
| Stochastic Oscillator | 82.12 | 0.68 |
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.